CN108245572A - The application of citrus fruits volatile oil and food, the drug of the volatile oil containing citrus fruits - Google Patents
The application of citrus fruits volatile oil and food, the drug of the volatile oil containing citrus fruits Download PDFInfo
- Publication number
- CN108245572A CN108245572A CN201810067145.1A CN201810067145A CN108245572A CN 108245572 A CN108245572 A CN 108245572A CN 201810067145 A CN201810067145 A CN 201810067145A CN 108245572 A CN108245572 A CN 108245572A
- Authority
- CN
- China
- Prior art keywords
- citrus fruits
- volatile oil
- weight
- parts
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020971 citrus fruits Nutrition 0.000 title claims abstract description 108
- 239000000341 volatile oil Substances 0.000 title claims abstract description 88
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 31
- 235000013305 food Nutrition 0.000 title claims abstract description 23
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 23
- 230000002124 endocrine Effects 0.000 claims abstract description 14
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 33
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 240000000560 Citrus x paradisi Species 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims description 4
- 240000002319 Citrus sinensis Species 0.000 claims description 4
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- -1 octenyl succinate anhydride Chemical class 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 201000010251 cutis laxa Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 abstract description 19
- 208000030172 endocrine system disease Diseases 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 description 39
- 241000700159 Rattus Species 0.000 description 33
- 238000011282 treatment Methods 0.000 description 32
- 238000003304 gavage Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000001543 one-way ANOVA Methods 0.000 description 8
- 210000001685 thyroid gland Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 6
- 241000207199 Citrus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010027304 Menopausal symptoms Diseases 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 5
- 101800000989 Oxytocin Proteins 0.000 description 5
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 206010029410 night sweats Diseases 0.000 description 5
- 230000036565 night sweats Effects 0.000 description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 5
- 229960001723 oxytocin Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000003689 pubic bone Anatomy 0.000 description 5
- 238000010010 raising Methods 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 241001672694 Citrus reticulata Species 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 208000027692 gas pain Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 229960002662 propylthiouracil Drugs 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000001646 thyrotropic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 229940035722 triiodothyronine Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- DSMKMBRLTGTLJE-UHFFFAOYSA-N 1-(oxo-$l^{3}-sulfanyl)propane Chemical compound CCC[S]=O DSMKMBRLTGTLJE-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000008346 uterine blood flow Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of the citrus fruits volatile oil in preparation adjusting endocrine is subtracted with alleviating primary dysmenorrhea, alleviation female climacteric syndrome, improvement first, improves prostatitic food, drug, its application range is widened, also to adjust endocrine to alleviate primary dysmenorrhea, alleviate female climacteric syndrome, improve first and subtract, improve the endocrine system diseases such as prostatitis and provide new way.
Description
Technical field
The present invention relates to a kind of application of citrus fruits volatile oil and food, the medicines of the volatile oil containing citrus fruits
Product.
Background technology
Citrus (scientific name：Citrus L.), a category of Rutaceae.Often claim citrus.It is mainly characterized by berry tool especially knot
Structure, therefore also known as mandarin orange fruit, the oil drop of exocarp are also known as oil vacuole, and middle pericarp innermost layer is white wire reticular structure, and referred to as tangerine is white or tangerine
Network, endocarp is by multiple carpels through reaching maturity and referred to as wooden dipper capsule is formed, and the cell development on wooden dipper capsule inner wall is into spindle half
The cutlet of transparent crystal shape is known as juice born of the same parents, and juice born of the same parents often have very thin handle.
Citrus fruits volatile oil main application is exactly to treat gastro-intestinal problems at present, can reconcile stomach, can also stimulate intestines
Peristole, help are vented；Can also calm alimentary canal, increase appetite, stimulate appetite；Citrus essential oil is very mild, infant, Yun Fuji
Old man can use, and especially infant's digestive system function is not yet complete, and easily hiccup or indigestion, all highly effective.
However at present, it not yet has been reported that and is used to adjust endocrine to alleviate primary dysmenorrhea, alleviate climacteric by citrus fruits volatile oil
Phase syndrome improves the application that first subtracts, improves the endocrine system diseases such as prostatitis.
Invention content
The purpose of the present invention is to provide citrus fruits volatile oil in medicine, a kind of new opplication in field of food, from
And widen its application range.
Technical solution is used by the present invention solves the above problems：
Citrus fruits volatile oil adjusts endocrine to alleviate primary dysmenorrhea, alleviate Menopause synthesis in preparation
Sign, the first that improves subtract, improve application in prostatitic food, drug.It is found that citrus fruits volatile oil can pass through adjusting
Endocrine restores thyroid function T3、T4、FT4、FT3, TSH, significantly alleviate first and subtract, weaken patient fatigue and weak, lethargic and drowsy state,
The first such as understandability reduction subtract symptom；It is found that citrus fruits volatile oil can significantly improve women climacteric by adjusting endocrine
Phase syndrome, decrease is scorching from head to foot, reduces dizziness, the number of palpitaition, night sweat；It is found that citrus fruits volatile oil can pass through tune
Prostatitis is significantly alleviated in section endocrine, weakens the parurias symptoms such as frequent micturition, urgent urination, perineum and pubis pain.It is sent out through experiment
Existing citrus fruits volatile oil, can significantly alleviate primary dysmenorrhea, adjust endocrine, reduce the severe pain time, lower pain
The effect of rank.
Preferably, citrus fruits use sweet orange, shatian pomelo, grape fruit, loose-skin orange or fingered citron.
Preferably, after the pericarp stripping and slicing of citrus fruits, using extraction by steam distillation and volatile oil is collected, then
Dehydration, obtains citrus fruits volatile oil.
Preferably, the food, drug use capsule, tablet or pressed candy or gel candy form.
Food, the drug of a kind of volatile oil containing citrus fruits, it is characterised in that：Including citrus fruits volatile oil.It should
Food, drug purposes be adjust endocrine with alleviate primary dysmenorrhea, alleviate female climacteric syndrome, improve first subtract,
Improve prostatitis.
Preferably, citrus fruits volatile oil is contained in citrus fruits volatile oil powdered oil or citrus fruits are waved
In hair oil tablet.
Preferably, further include one kind or more in filler, lubricant, preservative, sweetener, disintegrant, adhesive
Kind.
Preferably, filler includes dextrin, cyclodextrin and starch；Sweetener includes lactose, xylitol and D-sorbite；
Lubricant includes magnesium stearate；Preservative includes sodium benzoate；Disintegrant includes hydroxypropyl cellulose.
Preferably, the drug is by as follows into being grouped as：Citrus fruits volatile oil powdered oil 1-40 parts by weight, ring
Dextrin 5-30 parts by weight, starch 5-40 parts by weight, dextrin 5-30 parts by weight, lactose 5-60 parts by weight, xylitol 5-60 parts by weight,
D-sorbite 5-60 parts by weight, magnesium stearate 0.1-4 parts by weight, sodium benzoate 0.1-0.2 parts by weight, hydroxypropyl cellulose 2-10
Parts by weight.
Preferably, the drug is by as follows into being grouped as：30 parts by weight of citrus fruits volatile oil powdered oil, ring paste
Smart 25 parts by weight, 20 parts by weight of starch, 5 parts by weight of dextrin, 10 parts by weight of lactose, 15 parts by weight of xylitol, 15 weight of D-sorbite
Measure part, 0.8 parts by weight of magnesium stearate, 0.1 parts by weight of sodium benzoate, 5 parts by weight of hydroxypropyl cellulose.
Preferably, the preparation process of citrus fruits volatile oil powdered oil is as follows：Citrus fruits volatile oil, octene
After base succinic acid starch ester solution mixes in proportion, high speed shear, homogeneous under high pressure prepares citrus by the method for spray drying
Belong to fruit volatile oil powdered oil.
Preferably, spray drying condition is 190 DEG C of inlet air temperature, 90-100 DEG C of leaving air temp, sample introduction speed is 30mL/
Min, centrifugal atomizer rotating speed are 20000r/min.
Preferably, citrus fruits volatile oil, starch octenyl succinate anhydride solution press 1:4 mass ratio mixing.
The positive effect of the present invention is：The present invention provides citrus fruits volatile oil to adjust endocrine with slow
Solution primary dysmenorrhea alleviates female climacteric syndrome, improves food, medicine that first subtracts, improves the endocrine system diseases such as prostatitis
Its application range has been widened in application in product, is also integrated to adjust endocrine with alleviating primary dysmenorrhea, alleviating Menopause
Sign improves first and subtracts, improves the endocrine system diseases such as prostatitis and provide new way.
Specific embodiment
Below by embodiment, the present invention is described in further detail, following embodiment be explanation of the invention and
The invention is not limited in following embodiments.
Embodiment one
The present embodiment provides citrus fruits volatile oil to alleviating primary dysmenorrhea function zoopery verification：
Animal packet and modeling method：48 female sd inbred rats weigh after adaptability is fed 5 days, take tail blood, measure
Prostaglandin E2(PGE2), prostaglandin F2α(PGF2α) basic value, and rat is randomly divided into 6 according to two prostaglandin ratios
Group, respectively every group 8, blank control group, model control group, positive controls, low dose group, middle dose group, high dose group
Each group since 4d according to dosage daily early 9 when carry out gavage, continuous 8d.Each group continuous 10d since 1d it is daily 10 when carry out skin
Lower injection, blank control group injecting normal saline, remaining group injection estradiol benzoate injection, 1d1.0mg/, 2-
Only, only, last time injects oestradiol benzoate rear gavage, and in gavage 1h pneumoretroperitoneums for 24 hours to 10d 1.0mg/ to 9d 0.6mg/
Inject oxytocin 3U/ only.
1. rearing conditions：It raises in SPF grades of animal experimental centers, room ventilation condition is good, normal day-night change (8:
00am-8:00pm), relative humidity 50 ± 20%, 23 ± 1 DEG C of room temperature.
2. dosage：If citrus fruits volatile oil 0.025mL/d is only, 0.050mL/d, 0.075mL/d three
A dosage group, volatile oil with 2% Tween-80 hydrotropy, be mixed into 10% volatile oil solution carry out gavage, separately set blank control
Group and model control group, only, (clinical dosage is every to positive controls gavage TONGJINGBAO KELI to equal gavage distilled water 0.50mL/d
It 2 times, 1 bag every time, every bag 10 g).
3. result treatment：Single variance analysis ANOVA (One-way Analysis of Variance) is using SPSS 18.0
Software is handled, and experimental result is represented with mean value ± standard variance (Mean ± SD)；Linear regression analysis uses SPSS 18.0
Statistical software is handled, and experimental result is with Pearson correlation coefficient (Pearson Correlation Coefficient) table
Show, p<0.05 has significant difference, p<0.01 has pole significant difference.
4. result judgement：Waist and belly distortion patch ground can occur in abdominal pain for rat, and the situation that back leg pedals value is referred to as
Writhing response.In injection oxytocin 0.5h, compared to model control group, writhing number reduces, and writhing incubation period increases, PGF2α/
PGE2Ratio reduce, can determine that with alleviate primary dysmenorrhea effect.
5. result：
Influence of 1 different disposal of table to rat writhing response caused by oxytocin(n=8)
Table 1 Different treatments on body torsion in rats induced by
oxytocin(n=8)
| Group | Writhing incidence (%) | Writhing incubation period (min) | Writhing number in 30min |
| Blank | 0 | 30 | 0 |
| Model | 100 | 6.75±1.39** | 20.375±4.47** |
| It is positive | 62.5 | 23.75±4.89## | 2.375±2.00## |
| Low dosage | 87.5 | 16.375±6.25## | 8.75±4.27## |
| Middle dosage | 87.5 | 18.25±5.28## | 5.625±3.70## |
| High dose | 75 | 21.875±6.03## | 3.25±4.33## |
Note：Compared with blank group, * * p<0.01；Compared with model group, ##p<0.01；#p<0.05.
By table 1 as it can be seen that model control group is compared with blank control group, rat writhing incubation period and writhing number in 30min
Pole significant difference is respectively provided with, shows that primary dysmenorrhea model foundation is successful, and positive controls, low dose of citrus fruits volatile oil
Amount group, citrus fruits volatile oil middle dose group, citrus fruits volatile oil high dose group are turned round with the rat of model control group
Writhing number has pole significant difference in body incubation period and 30min, shows that citrus fruits volatile oil has and alleviates primary pain
The function of warp.
2 different disposal of table is to P of Rats GF caused by oxytocin2α/PGE2The influence of ratio(n=8)
Table2Different treatments on PGF2α/PGE2in rats induced by oxytocin(n=8)
| Group | Prostaglandin ratio |
| Blank | 0.72±0.08 |
| Model | 2.25±0.24** |
| It is positive | 0.87±0.18## |
| Low dosage | 0.85±0.14## |
| Middle dosage | 0.79±0.04## |
| High dose | 0.73±0.08## |
Note：Compared with blank group, * * p<0.01 (* * expressions p compared with blank group<0.01)；Compared with model group, ##p<
0.01；#p<0.05.
In women body, PGE2It can inhibit the spontaneous activity of uterine smooth muscle, and PGF2αThen promote uterine myometrium,
Uterine blood flow lowers, PGF2α/PGE2The raising of ratio causes uterine myometrium to aggravate, once endometrium is generated and is released
Let off more PGF2α, the two ratio is caused excessively to increase, the PGF of high concentration2αAct on the PGF on spiral arterioles wall2αReceptor,
Cause uterine smooth muscle spasmodic contraction, uterus ischemic and anoxic, acidic metabolite is piled up in muscle layer and leads to dysmenorrhoea.
As can be seen from Table 2, model control group is compared with blank control group, P of Rats GF2α/PGE2Ratio has pole significant difference,
Show the success of primary dysmenorrhea model foundation, and positive controls, citrus fruits volatile oil low dose group, citrus fruits are waved
Hair oil middle dose group, citrus fruits volatile oil high dose group extremely can significantly reduce P of Rats GF2α/PGE2Ratio shows
Citrus fruits, which have, adjusts endocrine, alleviates the function of primary dysmenorrhea.
Embodiment two
The preparation method of food, drug the present embodiment provides a kind of volatile oil containing citrus fruits, includes the following steps：
Step 1：The extraction of volatile oil：After the cleaning of citrus fruits fresh fruit, pericarp is cut, pericarp is cut into 8mm × 8mm
× 8mm fritters, with 1:4 solid-liquid ratios after extraction by steam distillation 2h, collect volatile oil and add in anhydrous sodium sulfate and take off
Water is filtered to get to citrus fruits volatile oil.Preferably, citrus fruits can be sweet orange, shatian pomelo, grape fruit, wide skin
Tangerine or fingered citron.
Step 2：Citrus fruits volatile oil, starch octenyl succinate anhydride solution are pressed 1:After 4 mass ratio mixing,
High speed shear under 4000r/min, homogeneous under 25MPa are prepared citrus fruits by the method for spray drying and volatilize oil powder
Powder oil, spray drying condition are 190 DEG C of inlet air temperature, and 90-100 DEG C of leaving air temp, sample introduction speed is 30mL/min, centrifuges mist
It is 20000r/min to change device rotating speed.
Step 3：Citrus fruits volatile oil powdered oil, filler, lubricant and preservative are mixed with drug,
Filler is dextrin, cyclodextrin and starch, and sweetener is lactose, xylitol and D-sorbite, and lubricant is tristearin
Sour magnesium, preservative are sodium benzoate, and disintegrant is hydroxypropyl cellulose.The drug is by as follows into being grouped as：Citrus fruits
Volatile oil powdered oil 1-40 parts by weight, cyclodextrin 5-30 parts by weight, starch 5-40 parts by weight, dextrin 5-30 parts by weight, lactose
5-60 parts by weight, xylitol 5-60 parts by weight, D-sorbite 5-60 parts by weight, magnesium stearate 0.1-4 parts by weight, sodium benzoate
0.1-0.2 parts by weight, hydroxypropyl cellulose 2-10 parts by weight.
Preferably, the drug is by as follows into being grouped as：30 parts by weight of citrus fruits volatile oil powdered oil, cyclodextrin
25 parts by weight, 20 parts by weight of starch, 5 parts by weight of dextrin, 10 parts by weight of lactose, 15 parts by weight of xylitol, 15 weight of D-sorbite
Part, 0.8 parts by weight of magnesium stearate, 0.1 parts by weight of sodium benzoate, 5 parts by weight of hydroxypropyl cellulose.
Primary dysmenorrhea model case：
The pain level of dysmenorrhoea is divided into following rank according to performance：
(1) pain level 0：Basic without pain
(2) pain level 1：There is pain but can be ignored easily
(3) pain level 2：There is pain, can not ignore but do not interfere daily life
(4) pain level 3：There is pain, can not ignore and disturbance of concentration
(5) pain level 4：There is pain, daily routines are affected
(6) pain level 5：Severe pain, needs to lie up
Case 1：Mr. Wang, female 23 years old, have 3 years or more primary dysmenorrhea medical histories, passing 3 days dysmenorrhoea time or more,
Middle severe pain 1 day, lower abdomen pendant pain are taken containing after citrus fruits volatilization oil product 4 days, menstrual onset, during severe pain
Between reduce to 2 hours, pain level is reduced to 2 by 3, and pain level reduces, and lower abdomen pendant pain weakens.
Case 2：Lee's ××, female 25 years old, have 6 years or more primary dysmenorrhea medical histories, passing 3 days dysmenorrhoea time, wherein acute
Strong pain 2 days, pain causes attention to be difficult to concentrate, lassitude, takes containing after citrus fruits volatilization oil product 9 days, the moon
Through rising, the severe pain time was reduced to 4 hours, and pain level is down to 3 by 5, and pain level lowers, and attention can be concentrated.
Case 3：All ××s, female 27 years old, have 9 years or more primary dysmenorrhea medical histories, passing 4 days dysmenorrhoea time, wherein acute
Strong pain 2 days, pain causes attention to be difficult to concentrate, lassitude, takes containing after citrus fruits volatilization oil product 10 days, the moon
Through rising, the severe pain time was reduced to a noon, and pain level is down to 2 by 4, and pain level lowers, and does not occur lassitude.
Citrus fruits volatile oil tablet replacement may be used in citrus fruits volatile oil powdered oil, and citrus fruits are waved
Hair oil tablet is made using absorbent to absorb citrus fruits volatile oil.
Embodiment three
The present embodiment provides a kind of preparation methods of the capsule of volatile oil containing citrus fruits, include the following steps：
Step 1：The extraction of volatile oil：Fresh citrus fruits, cut pericarp, and it is small that pericarp is cut into 8mm × 8mm × 8mm
Block, with 1:4 solid-liquid ratios after extraction by steam distillation 2h, collect volatile oil and add in anhydrous sodium sulfate dehydration, filtering,
Obtain citrus fruits volatile oil.
Step 2：With conventional pharmaceutical method, capsule skin, the weight ratio of glycerine, gelatin and water is made in glycerine, gelatin and water
Example is 5:2:6, and by above-mentioned citrus fruits volatile oil as in capsule skin.
Preferably, citrus fruits are sweet orange, shatian pomelo, grape fruit, loose-skin orange, fingered citron.
Example IV
The present embodiment provides citrus fruits volatile oil to improving prostatitis function zoopery verification：
Male SD rat 130, weight are 200~210g；Rearing conditions：It raises in SPF grades of animal experimental centers, it is indoor
Ventilation condition is good, normal day-night change (8:00am-8:00pm), relative humidity 50 ± 20%, 23 ± 1 DEG C of room temperature.
10 rats are taken, the ridge that breaks is put to death, and is carefully stripped prostata tissue, is weighed, and cool brine is cleaned, and the weight such as addition is high in advance
Temperature sterilizing the normal saline solution containing 0.5%TritonX-100, homogenate, 12000r/min centrifugation 30min, take supernatant, i.e., before
Row gland protein extract, ultraviolet light measure protein content.
SD rats are randomly divided into 4 groups, every group 30, i.e. blank group, Positive mode group, comparison model group, treatment group；
Modeling method：
Other than blank group rat, remaining each group rat makes prostatitis model：After measuring protein content, with physiology
Brine dilute obtains prostate purifying protein antigen liquid to 40g/L, then with not formula adjuvant measures emulsification again completely.0th day skin
Rat prostate protein purification liquid and endless is subcutaneously injected on the 21st day in lower injection rat prostate purifying protein antigen liquid 1.0mL
Complete not formula adjuvant 1:1 suspension 1.0mL, modeling success after 8 weeks.
Specific administration measure：
Treatment group, gavage citrus fruits volatile oil.
Positive mode group, gavage conventional antiinflammatory diuretic (the mould tromethamine of phosphorus dissipates).
Blank group and comparison model group do not take any drug, gavage distilled water.
14 days as a treatment course of successive administration；After each course for the treatment of, anesthetized rat 10, abdominal aorta blood sampling takes
After blood, blood leucocyte number, serum calcium ion concentration, serum T (testosterone) concentration are measured；And prostata tissue is taken, carry out pathology
Learn observation.
Result judgement：Upon administration, blood leucocyte number compared to comparison model group reduce, serum calcium ion concentration compared to pair
It is reduced according to model group, serum T (testosterone) concentration is reduced compared to comparison model group；Prostata tissue hyperemia is compared with oedema degree pair
It is reduced according to model group, then assert has improvement result to prostatitis.
Result treatment：Single variance analysis ANOVA (One-way Analysis of Variance) is soft using SPSS 18.0
Part is handled, and experimental result is represented with mean value ± standard variance (Mean ± SD).
After a course for the treatment of is administered, statistical result.
3 one course for the treatment of different disposals of table influence prostatitis rat model(n=10)
Table 3Different treatments on prostatitis model rats after one
treatment(n=10)
After three courses for the treatment of are administered, statistical result.
4 three course for the treatment of different disposals of table influence prostatitis rat model(n=10)
Table 4Different treatments on prostatitis model rats after three
treatments(n=10)
Data above shows that Positive mode group can alleviate prostatitis, Positive mode group and treatment group with treatment group
Blood leucocyte number, serum calcium ion concentration, the Serum testosterone concentrations of prostatitis rat model can be reduced.
Embodiment five
Prostatitis model case：
Zheng's ××, man, 50 years old, has 4 years chronic prostatitis medical histories, has frequent micturition, symptoms of urgency, and with pubis during urine
Pain, after taking containing citrus fruits volatilization oil product 10 days, pubis pain weakens during urine, and the urine frequency reduces.
Lee's ××, man, 48 years old, has 6 years chronic prostatitis medical histories, has frequent micturition, symptoms of urgency, and with pubis during urine
Pain, after taking containing citrus fruits volatilization oil product 8 days, pubis pain weakens during urine, and the urine frequency reduces, and is taking
After this citrus fruits volatile oil 30 days, symptoms of urgency is also weakened.
Embodiment six
Subtract function zoopery verification to improving first the present embodiment provides citrus fruits volatile oil：
Male Wistar rat 40, weight are 165~175g；Rearing conditions：It raises in SPF grades of animal experimental centers,
Room ventilation condition is good, normal day-night change (8:00am-8:00pm), relative humidity 50 ± 20%, 23 ± 1 DEG C of room temperature.
Wistar rats are randomly divided into 4 groups, every group 10, i.e. blank group, Positive mode group, comparison model group, treatment group；
Modeling method：
Positive mode group, comparison model group, treatment group are by 0.1% propylthiouracil by 1mL/100g weight gavages, sky
White group equivalent distilled water gavage, continuous gavage 2 weeks, rat eye socket take blood 2mL, centrifuge, take Virus monitory triiodo thyroid gland original ammonia
Sour T3, thyroxine T4, thyrotropic hormone sTSH.
Specific administration measure：
Treatment group, in modeling success after gavage citrus fruits volatile oil, and the next day gavage 0.1% propylthio oxygen of 2mg it is phonetic
Pyridine is to maintain rat first to subtract state.
Positive mode group, gavage conventional therapy first subtracts drug (thyroid tablet) after modeling success, and the next day gavage 2mg
0.1% propylthiouracil is to maintain rat first to subtract state.
Comparison model group, 0.1% propylthiouracil of gavage 2mg is to maintain rat first to subtract shape in after modeling success the next day
State.
Blank group, gavage distilled water.
Result judgement：Upon administration, free triiodothyronine concentration is compared to the raising of comparison model group, free first shape
Parathyrine concentration is reduced compared to the raising of comparison model group, thyrotropic hormone concentration compared to comparison model group, then assert and subtract tool to first
There is improvement result.
Result treatment：Single variance analysis ANOVA (One-way Analysis of Variance) is soft using SPSS 18.0
Part is handled, and experimental result is represented with mean value ± standard variance (Mean ± SD).
Each group thyroid function is as follows after treatment：
5 different disposal of table subtracts first rat model influence(n=10)
Table 5Different treatments on hypothyroidism model rats(n=10)
Data above shows that Positive mode group can improve first with treatment group and subtract, and Positive mode group can be carried with treatment group
High first subtracts the free triiodothyronine of rat model, free thyroxine concentration, and reduces thyrotropic hormone concentration.
Embodiment six
First subtracts model case：
Xing ×, female, 48 years old, first subtracted medical history within 5 years or more, on ordinary days feel loss of appetite, cold, malaise, lassitude,
Menostaxis, failure of memory, during hospital admission, thyroid function T3、T4、FT4、FT3It reduces, TSH raisings are diagnosed as allusion quotation
Type first subtracts.It takes and volatilizees oil product after 7 days containing citrus fruits, appetite increases, and spirit is improved, and is taken containing citrus fruits
Oil product volatilized after 2 months, first subtracts clinical symptoms disappearance, thyroid function T3、T4、FT4、FT3, TSH it is back to normal.
Mr. Wang, man, 52 years old, first subtracted medical history within 1 year, felt loss of appetite, malaise, dry skin on ordinary days, hospital is just
When examining, thyroid function T3、T4、FT4、FT3It reduces, TSH raisings are diagnosed as light-duty first and subtract.It takes and volatilizees containing citrus fruits
After oil product 30 days, first subtracts clinical symptoms disappearance, thyroid function T3、T4、FT4、FT3, TSH it is back to normal.
Embodiment seven
The zoopery of relieving menopausal syndrome function is verified the present embodiment provides citrus fruits volatile oil：
Female KM rats 45,15-16 monthly ages, weight are 295~305g；Rearing conditions：It raises in SPF grades of zooperies
Center, room ventilation condition is good, normal day-night change (8:00am-8:00pm), relative humidity 50 ± 20%, room temperature 23 ± 1
℃。
KM rats are randomly divided into 3 groups, every group 15, i.e. blank group, positive controls, treatment group；
Specific administration measure：
Treatment group, gavage citrus fruits volatile oil.
Positive mode group, gavage set aside all worries oral liquid.
Blank group does not take any drug, gavage distilled water.
Successive administration 21 days, during the experiment animal ad lib drinking-water, is anesthetized with ether each group rat, eyeball moves after 21 days
Arteries and veins takes blood, and cervical dislocation puts to death rat.Blood 3000r/min is centrifuged into 30min, draws upper serum, it is female using rat ELISA
Diol reagents box measures estradiol content.
Result judgement：Upon administration, serum estradiol concentration is increased compared to blank group, then assert to subtract first and make with improvement
With.
Result treatment：Single variance analysis ANOVA (One-way Analysis of Variance) is soft using SPSS 18.0
Part is handled, and experimental result is represented with mean value ± standard variance (Mean ± SD).
Experimental result is as follows：
6 different disposal of table influences menopausal syndrome rat model(n=15)
Table 6Different treatments on menopausal syndrome model rats(n
=15)
| Group | Serum estradiol content (pg/mL) |
| Blank group | 11.12±1.17 |
| Positive mode group | 16.53±1.41 |
| Treatment group | 14.96±1.28 |
Data above shows that Positive mode group can improve more with treatment group by improving estradiol content in rat blood serum
Term syndrome.
Embodiment eight
Menopausal syndrome model case：
Yellow ×, female, 47 years old, 2 years menopausal syndrome medical histories, on ordinary days scorching, easy palpitaition, easily raw night sweat, disorder of menstrual cycle, warp
Phase inferior belly gas pain is apparent, emotional instability.It takes and volatilizees oil product after 10 days containing citrus fruits, scorching decrease, night sweat number
It reduces, takes containing after citrus fruits volatilization oil product 20 days, menstruation is risen on time, and menstrual period inferior belly gas pain weakens.
Lv's ××, female, 48 years old, 1 year menopausal syndrome medical history, on ordinary days scorching, irritability, easily raw night sweat, abdominal distension under menstrual period
Pain is apparent.It takes and volatilizees oil product after 12 days containing citrus fruits, scorching decrease, night sweat number is reduced, and takes fruit containing Citrus
Real volatilization oil product is after 25 days, and menstruation is risen on time, and menstrual period inferior belly gas pain weakens.
Described in this specification above content is only illustrations made for the present invention.Extract citrus fruits
Volatile oil can also be added in food and other drugs, health products, so as to obtain adjust endocrine with alleviate primary pain
Through, alleviate female climacteric syndrome, improve first and subtract, improve the functions of the endocrine system diseases such as prostatitis.
Those skilled in the art can make various modifications to described specific embodiment
Or supplement or substitute in a similar way, content without departing from description of the invention or surmount the claims institute
The range of definition, is within the scope of protection of the invention.
Claims (13)
1. citrus fruits volatile oil prepare adjust endocrine with alleviate primary dysmenorrhea, alleviate female climacteric syndrome,
Improve first to subtract, improve application in prostatitic food, drug.
2. citrus fruits volatile oil application according to claim 1, it is characterised in that：Citrus fruits using sweet orange,
Shatian pomelo, grape fruit, loose-skin orange or fingered citron.
3. citrus fruits volatile oil application according to claim 1, it is characterised in that：The pericarp stripping and slicing of citrus fruits
Afterwards, using extraction by steam distillation and volatile oil is collected, subsequent dewatering obtains citrus fruits volatile oil.
4. citrus fruits volatile oil application according to claim 1, it is characterised in that：The food, drug use glue
Capsule, tablet or pressed candy or gel candy form.
5. food, the drug of a kind of volatile oil containing citrus fruits, it is characterised in that：Including citrus fruits volatile oil.
6. food, the drug of the volatile oil according to claim 5 containing citrus fruits, it is characterised in that：Citrus fruits
Volatile oil is contained in citrus fruits volatile oil powdered oil or citrus fruits volatile oil tablet.
7. food, the drug of the volatile oil according to claim 5 containing citrus fruits, it is characterised in that：Further include filling
It is one or more in agent, lubricant, preservative, sweetener, disintegrant, adhesive.
8. food, the drug of the volatile oil according to claim 7 containing citrus fruits, it is characterised in that：Filler includes
Dextrin, cyclodextrin and starch；Sweetener includes lactose, xylitol and D-sorbite；Lubricant includes magnesium stearate；Preservative packet
Include sodium benzoate；Disintegrant includes hydroxypropyl cellulose.
9. food, the drug of the volatile oil according to claim 5 containing citrus fruits, it is characterised in that：The drug by
As follows into being grouped as：Citrus fruits volatile oil powdered oil 1-40 parts by weight, cyclodextrin 5-30 parts by weight, starch 5-40 weight
Part, dextrin 5-30 parts by weight, lactose 5-60 parts by weight, xylitol 5-60 parts by weight, D-sorbite 5-60 parts by weight, magnesium stearate
0.1-4 parts by weight, sodium benzoate 0.1-0.2 parts by weight, hydroxypropyl cellulose 2-10 parts by weight.
10. food, the drug of the volatile oil according to claim 9 containing citrus fruits, it is characterised in that：The drug by
As follows into being grouped as：30 parts by weight of citrus fruits volatile oil powdered oil, 25 parts by weight of cyclodextrin, 20 parts by weight of starch, paste
Smart 5 parts by weight, 10 parts by weight of lactose, 15 parts by weight of xylitol, 15 parts by weight of D-sorbite, 0.8 parts by weight of magnesium stearate, benzene first
Sour 0.1 parts by weight of sodium, 5 parts by weight of hydroxypropyl cellulose.
11. food, the drug of the volatile oil according to claim 6 containing citrus fruits, it is characterised in that：Citrus fruits
The preparation process of volatile oil powdered oil is as follows：Citrus fruits volatile oil, starch octenyl succinate anhydride solution mix in proportion
After conjunction, high speed shear, homogeneous under high pressure prepares citrus fruits volatile oil powdered oil by the method for spray drying.
12. food, the drug of the volatile oil according to claim 11 containing citrus fruits, it is characterised in that：Spray drying
Condition is 190 DEG C of inlet air temperature, and 90-100 DEG C of leaving air temp, sample introduction speed is 30mL/min, and centrifugal atomizer rotating speed is
20000r/min。
13. food, the drug of the volatile oil according to claim 11 containing citrus fruits, it is characterised in that：Citrus fruit
Real volatile oil, starch octenyl succinate anhydride solution press 1:4 mass ratio mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810067145.1A CN108245572B (en) | 2018-01-24 | 2018-01-24 | Application of citrus fruit volatile oil and medicine containing citrus fruit volatile oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810067145.1A CN108245572B (en) | 2018-01-24 | 2018-01-24 | Application of citrus fruit volatile oil and medicine containing citrus fruit volatile oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108245572A true CN108245572A (en) | 2018-07-06 |
| CN108245572B CN108245572B (en) | 2021-08-10 |
Family
ID=62742178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810067145.1A Active CN108245572B (en) | 2018-01-24 | 2018-01-24 | Application of citrus fruit volatile oil and medicine containing citrus fruit volatile oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108245572B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507717A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Citrus fruits volatile oil prepare Dealcoholic sobering-up food, food, the drug of the application in drug and its preparation |
| CN110507723A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Food, the drug of application and its preparation of the citrus fruits volatile oil in the internal inflammation food of preparation alleviation, drug |
| CN110507721A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Food, the drug of application and its preparation of the citrus fruits volatile oil in preparation raising antioxidant ability of organism food, drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861159A (en) * | 2012-10-19 | 2013-01-09 | 成都中医药大学附属医院 | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof |
| CN103948022A (en) * | 2014-04-01 | 2014-07-30 | 新时代健康产业（集团）有限公司 | Qi stagnation physique health food and making method thereof |
| CN104116820A (en) * | 2014-07-27 | 2014-10-29 | 林大利 | Zhitejia tablet (for treating haemorrhoid quickly) and preparation method thereof |
-
2018
- 2018-01-24 CN CN201810067145.1A patent/CN108245572B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102861159A (en) * | 2012-10-19 | 2013-01-09 | 成都中医药大学附属医院 | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof |
| CN103948022A (en) * | 2014-04-01 | 2014-07-30 | 新时代健康产业（集团）有限公司 | Qi stagnation physique health food and making method thereof |
| CN104116820A (en) * | 2014-07-27 | 2014-10-29 | 林大利 | Zhitejia tablet (for treating haemorrhoid quickly) and preparation method thereof |
Non-Patent Citations (8)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110507717A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Citrus fruits volatile oil prepare Dealcoholic sobering-up food, food, the drug of the application in drug and its preparation |
| CN110507723A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Food, the drug of application and its preparation of the citrus fruits volatile oil in the internal inflammation food of preparation alleviation, drug |
| CN110507721A (en) * | 2019-06-14 | 2019-11-29 | 河北成弘生物科技有限公司 | Food, the drug of application and its preparation of the citrus fruits volatile oil in preparation raising antioxidant ability of organism food, drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108245572B (en) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sultana et al. | Clinical update and treatment of lactation insufficiency | |
| CN108245572A (en) | The application of citrus fruits volatile oil and food, the drug of the volatile oil containing citrus fruits | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN104352552B (en) | A kind of food, health products or pharmaceutical composition | |
| Strauss | THE THERAPEUTIC USE OF VITAMIN B, IN POLYNEURITIS AND CARDIOVASCULAR CONDITIONS: CLINICAL INDICATIONS | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN112386589A (en) | Composition for anti-anxiety/anti-depression agent and application thereof | |
| CN101810679A (en) | Polyunsaturated fatty acid soft capsule and preparation method thereof | |
| Sandstead | Clinical manifestations of certain classical deficiency diseases | |
| CN104189356B (en) | A kind of pharmaceutical composition for the treatment of or auxiliary treatment infertility and its production and use | |
| Rushton | The endocrine system | |
| CN106074714B (en) | It is a kind of to treat irritable bowel syndrome pharmaceutical composition | |
| EP3530267B1 (en) | Composition comprising pinitol for use in the prevention or treatment of female menopausal symptoms | |
| CN100488519C (en) | Medicine for treating dysmenorrhea and its preparing method | |
| CN109223766A (en) | Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body | |
| Wright | Polyavitaminosis and asulphurosis | |
| CN1053369C (en) | Medicine for treating thyreoidism | |
| CN105770205A (en) | Pharmaceutical composition containing felodipine and capable of treating hypertension and preparation method thereof | |
| CN101700119A (en) | Oral administration preparation for improving subhealth symptom of adult | |
| CN105998198A (en) | Health product for improving hyperlipidemia, hyperglycemia and hypertension and preparation method thereof | |
| CN105687765A (en) | Lacidipine containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN101584793B (en) | Pure natural health-care four-Huai medicine | |
| CURE | AN AYURVEDIC AND CONTEMPRORY OVERVEIW OF LACTATION INSUFFICIENCY AND ITS CURE: A CONCEPTUAL APPROACH | |
| Sharma | Clinical study on effect of swarnamritaprashana (modified Swarna Prashana) in the management of Shayyamutra in Children | |
| CN113842417A (en) | Herbal formula for relieving and helping sleep and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |